Haruna Kawano Selected Research

K 130

1/2020

Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Haruna Kawano Research Topics

Disease

6	Autosomal Dominant Polycystic Kidney (ADPKD) 05/2021 - 10/2015
1	Dysbiosis 04/2022
1	Prostatic Neoplasms (Prostate Cancer) 04/2022
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2020
1	Disease Progression 12/2015
1	Teratoma (Teratoid Tumor) 11/2015
1	Cysts 10/2015
1	Tuberous Sclerosis (Bourneville's Disease) 05/2015
1	Neoplasms (Cancer) 05/2015

Drug/Important Bio-Agent (IBA)

4	Tolvaptan FDA Link 05/2021 - 10/2015
2	TEMPOIBA 05/2021 - 10/2015
2	Biomarkers (Surrogate Marker)IBA 12/2015 - 10/2015
1	AndrogensIBA 04/2022
1	Indicators and Reagents (Reagents)IBA 04/2022
1	Testosterone (Sustanon)FDA Link 04/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 04/2022
1	K 130IBA 01/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2018
1	Adenosine Monophosphate (AMP)IBA 12/2015
1	Vasopressins (Vasopressin)IBA 12/2015
1	Arginine Vasopressin (Argipressin)IBA 12/2015
1	TOR Serine-Threonine KinasesIBA 11/2015
1	Mechanistic Target of Rapamycin Complex 1IBA 11/2015
1	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 10/2015
1	Macrophage Colony-Stimulating FactorIBA 10/2015
1	trans-sodium crocetinate (crocetin)IBA 05/2015

Therapy/Procedure

2	Therapeutics 04/2022 - 10/2015